Mouse Recombinant LAG3 protein, hFc Tag (V2LY-0526-LY8602)

Go to compare Compare Online Inquiry
Request for COA
Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Expressed Host
HEK293 Cells
Protein Species
Mouse
Tag
hFc Tag
Protein Construction
This product is Mouse Recombinant LAG3 protein, hFc Tag consist of Amino Acid: 1-432 and predicts a molecular mass of 71.1 kDa.
Molecule Mass
71.1 kDa
Sequence
Amino Acid: 1-432
Species
Mouse

Formulations & Storage [For reference only, actual COA shall prevail!]

Purity
>95% as determined by SDS-PAGE.
Endotoxin
Please contact us for more information.
Format
Lyophilized
Reconstitution
Allow the vial and reconstitution buffer to equilibrate to room temperature. Briefly centrifuge or tap down the vial to ensure that all lyophilized powder is collected at the bottom of the vial. For the reconstitution of this product, we recommend adding PBS or sterile water to achieve a final antibody concentration of 1 mg/mL. Allow the vial to reconstitute for 10-15 minutes at room temperature with gentle agitation. Avoid vigorous shaking that can cause foaming and antibody denaturation. Aliquot into volumes based on your experiment and store liquid protein at -20°C or -80°C for long time.
Buffer
Lyophilized from sterile Tris, NaCl, Arginine, Glycerol
Preservative
None
Storage
Samples are stable for up to twelve months from date of receipt at -20°C to -80°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
More Infomation

Target

Full Name
lymphocyte activating 3
Alternative Names
lymphocyte activating 3
Function
Lymphocyte activation gene 3 protein: Inhibitory receptor on antigen activated T-cells (PubMed:7805750, PubMed:8647185, PubMed:20421648).
Delivers inhibitory signals upon binding to ligands, such as FGL1 (By similarity).
FGL1 constitutes a major ligand of LAG3 and is responsible for LAG3 T-cell inhibitory function (By similarity).
Following TCR engagement, LAG3 associates with CD3-TCR in the immunological synapse and directly inhibits T-cell activation (By similarity).
May inhibit antigen-specific T-cell activation in synergy with PDCD1/PD-1, possibly by acting as a coreceptor for PDCD1/PD-1 (By similarity).
Negatively regulates the proliferation, activation, effector function and homeostasis of both CD8(+) and CD4(+) T-cells (PubMed:7805750, PubMed:8647185, PubMed:20421648).
Also mediates immune tolerance: constitutively expressed on a subset of regulatory T-cells (Tregs) and contributes to their suppressive function (By similarity).
Also acts as a negative regulator of plasmacytoid dendritic cell (pDCs) activation (By similarity).
Binds MHC class II (MHC-II); the precise role of MHC-II-binding is however unclear (PubMed:8647185).
Secreted lymphocyte activation gene 3 protein
May function as a ligand for MHC class II (MHC-II) on antigen-presenting cells (APC), promoting APC activation/maturation and driving Th1 immune response.
Biological Process
Adaptive immune responseIEA:UniProtKB-KW
Cell surface receptor signaling pathwayISS:UniProtKB
Negative regulation of interleukin-2 productionIEA:Ensembl
Negative regulation of regulatory T cell differentiationISS:UniProtKB
Plasmacytoid dendritic cell activationISS:UniProtKB
Positive regulation of natural killer cell mediated cytotoxicityIEA:Ensembl
Regulation of immune responseISS:UniProtKB
Cellular Location
Lymphocyte activation gene 3 protein:
Cell membrane
Secreted lymphocyte activation gene 3 protein:
Secreted
Produced following cleavage of the main chain.
Topology
Extracellular: 23-450
Helical: 451-471
Cytoplasmic: 472-525
PTM
Lymphocyte activation gene 3 protein
Proteolytically cleaved by ADAM10 and ADAM17 within the connecting peptide region, leading to release of Secreted lymphocyte activation gene 3 protein (sLAG-3). ADAM10 mediates constitutive cleavage, but cleavage increases following T-cell activation, whereas shedding by ADAM17 is induced by TCR signaling in a PRKCQ-dependent manner.

Zhao, L., Wang, H., Xu, K., Liu, X., & He, Y. (2022). Update on lymphocyte-activation gene 3 (LAG-3) in cancers: From biological properties to clinical applications. Chinese Medical Journal, 135(10), 1203-1212.

Lythgoe, M. P., Liu, D. S. K., Annels, N. E., Krell, J., & Frampton, A. E. (2021). Gene of the month: Lymphocyte-activation gene 3 (LAG-3). Journal of Clinical Pathology, 74(9), 543-547.

Slevin, S. M., Garner, L. C., Lahiff, C., Tan, M., Wang, L. M., Ferry, H., ... & Keshav, S. (2020). Lymphocyte activation gene (LAG)-3 is associated with mucosal inflammation and disease activity in ulcerative colitis. Journal of Crohn's and Colitis, 14(10), 1446-1461.

Gebauer, F., Krämer, M., Bruns, C., Schlößer, H. A., Thelen, M., Lohneis, P., ... & Quaas, A. (2020). Lymphocyte activation gene-3 (LAG3) mRNA and protein expression on tumour infiltrating lymphocytes (TILs) in oesophageal adenocarcinoma. Journal of cancer research and clinical oncology, 146, 2319-2327.

Atkinson, V., Khattak, A., Haydon, A., Eastgate, M., Roy, A., Prithviraj, P., ... & Triebel, F. (2020). Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma. Journal for immunotherapy of cancer, 8(2).

Yu, X., Huang, X., Chen, X., Liu, J., Wu, C., Pu, Q., ... & Zhou, L. (2019, August). Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy. In MAbs (Vol. 11, No. 6, pp. 1139-1148). Taylor & Francis.

Ruffo, E., Wu, R. C., Bruno, T. C., Workman, C. J., & Vignali, D. A. (2019, April). Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor. In Seminars in immunology (Vol. 42, p. 101305). Academic Press.

Saleh, R. R., Peinado, P., Fuentes-Antrás, J., Pérez-Segura, P., Pandiella, A., Amir, E., & Ocaña, A. (2019). Prognostic value of lymphocyte-activation gene 3 (LAG3) in cancer: a meta-analysis. Frontiers in oncology, 9, 1040.

Zhang, Y., Liu, Y. D., Luo, Y. L., Liu, B. L., Huang, Q. T., Wang, F., & Zhong, Q. (2018). Prognostic value of lymphocyte activation gene-3 (LAG-3) expression in esophageal squamous cell carcinoma. Journal of Cancer, 9(22), 4287.

Wang, Y., Dong, T., Xuan, Q., Zhao, H., Qin, L., & Zhang, Q. (2018). Lymphocyte-activation gene-3 expression and prognostic value in neoadjuvant-treated triple-negative breast cancer. Journal of breast cancer, 21(2), 124-133.

Ask a question We look forward to hearing from you.
0 reviews or Q&As
Loading...
Have you used Mouse Recombinant LAG3 protein, hFc Tag?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

online inquiry
Online Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.